A Treatment Access Program To Provide Maraviroc To Eligible Adult Patients Completing A4001050 Study Until Commercial Availability Of Maraviroc (Celsentri) In India

N/ANo Longer AvailableNCT00992654

ViiV Healthcare

Overview

The new protocol will allow the patients enrolled on A4001050 to have continuous access of Maraviroc and the treatment will not be interrupted until the drug is commercially available in India.

Study Type

EXPANDED_ACCESS

Conditions

Human Immunodeficiency Virus (HIV)

Interventions

Open Label Treatment Access: MaravirocDRUG

Oral dosing twice daily. The dose will depend on the optimized background therapy.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Subjects who complete the A4001050 study and are continuing to derive benefit from Maraviroc. * Subjects who are willing and able to comply with scheduled visits, treatment plan and other study procedures. Exclusion Criteria: * Subjects who discontinued in A4001050 study. * Unable to provide consent.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.